Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice

Código QR

Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice

To report the early efficacy and safety outcomes of treatment with intravitreal injections of brolucizumab (IVT-B) in patients presenting neovascular age-related macular degeneration (nAMD) in a tertiary clinical setting. A retrospective case series of patients that received IVT-B with a minimum of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andrea Montesel, Claudio Bucolo, Ferenc B. Sallo, Chiara M. Eandi
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	brolucizumab anti-vascular endothelial growth factor intravitreal route neovascular age-related macular degeneration retina choroid Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/66aad92b4f694e8eb652eb40ee06dae7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
por: Yannuzzi NA, et al.
Publicado: (2019)

Side Effects of Brolucizumab
por: Tahmineh Motevasseli, et al.
Publicado: (2021)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
por: Chakraborty D, et al.
Publicado: (2021)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
por: Nudleman E, et al.
Publicado: (2016)

Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes
por: Pedrosa AC, et al.
Publicado: (2016)

Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration
por: Balaratnasingam C, et al.
Publicado: (2015)

The Impact of Non-Ophthalmic Factors on Intravitreal Injections During the COVID-19 Lockdown
por: Ashrafzadeh S, et al.
Publicado: (2021)

A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
por: Hykin P, et al.
Publicado: (2016)

Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
por: Cheema MR, et al.
Publicado: (2021)

Management of neovascular age-related macular degeneration: Taiwan expert consensus
por: Ling Yeung, et al.
Publicado: (2021)

Real-World Anti-Vascular Endothelial Growth Factor Therapy Outcomes in Myopic Choroidal Neovascularization
por: Bhatia D, et al.
Publicado: (2021)

Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization
por: Tan CS, et al.
Publicado: (2017)

Real-World Effectiveness, Treatment Pattern, and Safety of Ranibizumab in Korean Patients with Neovascular Age-Related Macular Degeneration: Subgroup Analyses from the LUMINOUS Study
por: Sagong M, et al.
Publicado: (2021)

Vision Recovery Velocity, Momentum and Acceleration: Advanced Vitreoretinal Analytics as Measure of Treatment Efficacy for Neovascular Age-Related Macular Degeneration
por: Almeida DRP, et al.
Publicado: (2021)

Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment
por: Pongsachareonnont P, et al.
Publicado: (2018)

Quantitative Comparison of the Vascular Structure of Macular Neovascularizations Between Swept-Source and Spectral-Domain Optical Coherence Tomography Angiography
por: Faatz H, et al.
Publicado: (2020)

Idiopathic polypoidal choroidal vasculopathy in Thai patients with clinical and angiographic choroidal neovascularization
por: Bhoomibunchoo C, et al.
Publicado: (2017)

Trends in Real-World Neovascular AMD Treatment Outcomes in the UK
por: Mehta H, et al.
Publicado: (2020)

Neovascular age-related macular degeneration without drusen in the fellow eye: clinical spectrum and therapeutic outcome
por: Chung WH, et al.
Publicado: (2016)

The Evolving Treatment of Diabetic Retinopathy
por: Mansour SE, et al.
Publicado: (2020)

One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement
por: Hirakata T, et al.
Publicado: (2016)

Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date
por: Chen ER, et al.
Publicado: (2020)

Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up
por: Yan Lu, et al.
Publicado: (2021)

Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study
por: Takahashi K, et al.
Publicado: (2018)

Real-World Outcomes of Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration: A Large-Scale Postmarketing Surveillance in Korea
por: Ryu G, et al.
Publicado: (2021)

Treatment Course of Patients with Exudative Age-Related Macular Degeneration Using Ocular Hypotensives
por: Modjtahedi BS, et al.
Publicado: (2020)

Spotlight on reticular pseudodrusen
por: Rabiolo A, et al.
Publicado: (2017)

Long-Term Favorable Visual Outcomes in Patients with Large Submacular Hemorrhage
por: Iyer PG, et al.
Publicado: (2021)

The 2-Year Leakage Index and Quantitative Microaneurysm Results of the RECOVERY Study: Quantitative Ultra-Widefield Findings in Proliferative Diabetic Retinopathy Treated with Intravitreal Aflibercept
por: Amy S. Babiuch, et al.
Publicado: (2021)

Treatment of myopic choroidal neovascularization with intravitreal ranibizumab injections: the role of age
por: Karagiannis D, et al.
Publicado: (2017)

To Peel or Not to Peel: Pars Plana Vitrectomy with Macular Membrane Peel in Eyes with Abnormalities of Vitreomacular Interface and Coexisting Dry Age-Related Macular Degeneration
por: Furashova O, et al.
Publicado: (2020)

Baseline Subfoveal Choroidal Thickness as a Predictor for Response to Short-Term Intravitreal Bevacizumab Injections in Diabetic Macular Edema
por: Dweikat A, et al.
Publicado: (2021)

Comparison of choroidal neovascularization secondary to white dot syndromes and age-related macular degeneration by using optical coherence tomography angiography
por: Wang JC, et al.
Publicado: (2018)

Choroidal Neovascularization in Pediatric Patients: Analysis of Etiologic Factors, Clinical Characteristics and Treatment Outcomes
por: Ting Zhang, et al.
Publicado: (2021)

Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
por: Spooner K, et al.
Publicado: (2017)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
por: Garweg JG
Publicado: (2019)

Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning
por: Miyamoto N, et al.
Publicado: (2017)

The Anti-Inflammatory Effect of Hydrogen Gas Inhalation and Its Influence on Laser-Induced Choroidal Neovascularization in a Mouse Model of Neovascular Age-Related Macular Degeneration
por: I-Chia Liang, et al.
Publicado: (2021)

Guidelines for the Management of Center-Involving Diabetic Macular Edema: Treatment Options and Patient Monitorization
por: Figueira J, et al.
Publicado: (2021)

Polypoidal choroidal vasculopathy (PCV): the 4-year review of the real-life treatment experiences
por: Ratanasukon M, et al.
Publicado: (2018)